Roivant Sciences

Overview

Roivant Sciences is a biopharmaceutical company founded in 2014[4] with headquarters in New York, NY and Basel, Switzerland[1]. The company develops and commercializes medicines and technologies by building agile, focused subsidiary companies called "Vants"[2][3], employing technology across discovery, development and commercialization[2]. Roivant's subsidiaries include Immunovant, which focuses on autoimmune disease therapies; Priovant, which develops targeted therapies for severe autoimmune disease; and Pulmovant, which focuses on pulmonary disease treatments[7]. The company reports 12 positive Phase 3 trials since 2019 and 8 FDA approvals[5]. Roivant's first commercial launch was VTAMA (tapinarof) cream, 1%, approved for plaque psoriasis in adults and launched in 2022[6]. The company continues to operate as an independent entity, though its subsidiary Dermavant was acquired by Organon in 2024[8].

Headquarters listed as New York, NY and Basel, Switzerland [2]

Roivant Sciences was founded in 2014. [4]

Roivant's commercial launch was VTAMA (tapinarof) cream, 1%, approved for plaque psoriasis in adults and launched in 2022. [6]

Roivant's subsidiaries include Immunovant (autoimmune disease therapies), Priovant (targeted therapies for severe autoimmune disease) and Pulmovant (pulmonary disease treatments). [7]

Roivant's New York office is at 1 Pennsylvania Plaza, 54th Floor, New York, NY 10119, with a second office at Viaduktstrasse 8, 4051 Basel, Switzerland. [9]

Growth & traction

Roivant reports 12 positive Phase 3 trials since 2019 and 8 FDA approvals. [5]